Rebirth of the God-level Xueba

Given Frankie three hundred pig brains, he never expected that Yang Rui would go to develop new medicines.

Give Franky another 600 pig brains, and Franky can't imagine that Yang Rui actually produced the active substance when he said to develop a new drug.

Of course, active substances can still be regarded as drugs. The process of developing new drugs is extremely cumbersome. If the work in the laboratory is allocated according to the workload, it may be less than half of the total work. The part that Yang Rui has done so far, It's far away from a third of the laboratory work.

Still, French hadn't heard anything like it from other companies.

Arnold, who was seduced by him, had never heard anything similar.

In fact, compared to Frankie's habit of being shocked, Comrade Arnold faced the shock with the attitude of an entry-level player. After entering the door of Huarui Lab, Arnold couldn't help but whispered to Frankie: "It's only been a few days?" You haven't heard that he is doing this work? "

"Of course not. He was working on the coenzyme Q10 catalyst a few days ago. Didn't he write a book in the past two months? It sold very well, and it was a professional bestseller." Pay attention to Yang Rui, if it weren't for China not having a well-developed media and information industry in Europe and America, Frank would have investigated Yang Rui to the bottom.

Arnold was the person in charge who negotiated the catalyst contract with Yang Rui two months ago. During his stay in Beijing, he was basically negotiating terms with Japanese and Norwegian companies.

In other words, several multinational corporations are so procrastinating, they want to see the development of the situation, but also want to lower Yang Rui's quotation.

After all, no matter how high the profit of the drug is, there is no reason to give Yang Rui 5% of the dry stock in vain, and it is a dividend of global sales. Although Coenzyme Q10 is far from being a blockbuster drug, even a quasi-blockbuster, it is still a medium-sized product with annual sales of over 100 million for a single company. Besides, what if it becomes a blockbuster? ?

You can't give Yang Rui 50 million U.S. dollars every year. Such an agreement, the British feel painful when they think about it.

Even now, with the sales volume of coenzyme Q10, 2% of the income dividend is quite a lot.

Medicines are products with extremely high profits. The only high-priced raw material used in semi-synthetic coenzyme Q10 is refined solanesol. In a stable market, Zeneca can usually get more than 30% of profits and 2% of income dividends It is equivalent to 0.6% to enjoy dividends. Based on the current annual sales of Coenzyme Q10 of more than 100 million US dollars, it is equivalent to a stable income of 600,000 US dollars per year, which is quite a lot and there is still room for growth.

This is also an excellent condition for biologists,

Even a well-known professor in the United States, if he signs a contract and can get 600,000 US dollars without drought or flood, he should be happy.

Unfortunately, Yang Rui was not satisfied.

Arnold and his colleagues from other countries can only spend time in tacit understanding.

However, this is just a catalyst formula for coenzyme Q10. If it was replaced with something like interferon, there would definitely be no tacit understanding among the various companies, and they would have been crazy about it.

In order to obtain a drug, the price that large pharmaceutical companies are willing to pay is unimaginable to ordinary people. For example, in order to obtain Lipitor, Pfizer finally acquired its development company Lambert for US$82.4 billion. While the latter’s shareholders made a profit, Pfizer also obtained a total sales volume of US$130 billion from Lipitor. Its peak annual sales were $13 billion, more than the government tax revenues of many countries.

However, a catalyst that can increase the production of a drug is not an exclusive drug after all.

Arnold also put aside the matter of the catalyst for the time being, looked at Yang Rui's experimental records, and asked, "What kind of cooperation do you want?"

"This is the first time we have developed a drug, so we need any kind of cooperation." Yang Rui shrugged and said, "It's mainly about information. If you want it, I can pay a consulting fee."

"Consulting fee? How much?"

"$10,000, airfare and hotel reimbursement."

Arnold laughed dumbfounded: "Ten thousand dollars is not enough to hire an investigator."

"I know." Yang Rui smiled.

Arnold's face changed: "Do you want Jie Likang to work for nothing?"

"It's not a bad thing for you to send two people to participate and keep abreast of our progress, right?"

"That's impossible." Arnold smiled. He wanted to say that you gave Zeneca the formula of the coenzyme Q10 catalyst to Zeneca, but this time is not suitable for mentioning this matter, so Arnold endured it.

Yang Rui shrugged and said: "Then don't cooperate. I invite you to be observers. If you want to say it, you can say it. If you don't want to say it, it's in your interest, right?"

"No need to sign a contract?" Arnold's heart moved, and there was no harm in understanding the situation unilaterally.

Yang Rui shook his head: "At least sign a confidentiality contract."

"After signing the contract, what are you still observing? An observer who cannot report..."

"You just report the results, and you don't need to talk about the process." Deferiprone, which has just arrived at the synthesis stage, as long as it is not allowed to be seen by a professional pharmacologist or photographed, it will not reveal much.

Because of Yang Rui's relationship, Arnold was indeed very curious, and couldn't help hesitating.

"Why don't you just be an observer for a day, let's see." Yang Rui then asked the company lawyer waiting in the laboratory to come over and give Arnold a non-disclosure agreement to sign.

Arnold refused, but read the agreement carefully and signed it.

"Old Wei, show it to the British gentlemen." Yang Rui gave them white coats, led them into the laboratory, and introduced deferiprone.

It was impossible for Yang Rui to offer Zeneca the normal price, because he couldn't afford it. The medical industry is an industry with a healthy industrial chain. Every job has a price, and they are all ridiculously expensive.

For example, the most disturbing clinical trials, many people think that clinical trials are drug research conducted by pharmaceutical companies in conjunction with hospitals or independently, but in fact, there have been clinical trial companies in Europe and the United States a long time ago, and they specialize in providing medical services for various pharmaceutical companies. The annual sales of clinical trial services exceed 1 billion.

As for professional consulting companies, they are usually deceitful, but the fees are ridiculously expensive, and the price of millions of dollars is just the beginning.

Now, pharmaceutical companies often spend tens of millions or even hundreds of millions of dollars for preclinical research, half of which is spent outside the laboratory, and Yang Rui cannot afford this money.

His income mainly comes from Zeneca's dividends, and his expenditure is mainly used for legal fees. The former can be slightly more than the latter, which is enough for Yang Rui to carry out some experiments that are difficult to carry out in China, such as the synthesis of deferiprone, but after the synthesis , the amount of money spent on any part is beyond Yang Rui's ability to afford, let alone outsource it to Zeneca.

In fact, many domestic laboratories in later generations do outsourced work from abroad, such as animal experiments, and the determination of active ingredients, etc., which are complicated and quite profitable, but in essence, they are similar to Foxconn. It is the profits extracted by reducing costs, and the costs that are reduced are usually scientific researchers, or students of tutors, or young masters and doctors who have just graduated.

In the long industrial chain of pharmaceuticals, the higher the upper layer, the higher the capital required, the greater the risk, and the greater the profit.

Domestic companies and laboratories are small and weak, and they cannot produce original drugs without outsourcing.

Even the research and development of original drugs in the 1980s was not something that Chinese laboratories could undertake.

In this regard, Yang Rui has something to ask of Zeneca.

Asking for help is not a comfortable thing, but you are not as skilled as others, and you have to bow your head when you should bow your head.

Making medicine is not making art. Those who make art can advocate strong orders, feign grievances, be indignant or angry, take it for granted or dismiss it.

But those who make medicines are inferior to others and still bow their heads. They are wasting their own time and energy, wasting their accumulation and the trust of people around them.

These time, energy, accumulation and trust are often in units of ten years.

The only people who can do this kind of thing are bureaucrats, artists and beasts, wasting ten years of one or even several researcher's elites, just to not bow their heads once.

Yang Rui is not one of them.

As a novice in the pharmaceutical field, Yang Rui has very little experience. Unlike writing papers or monographs, Yang Rui's contact with pharmaceutical factories is limited to the laboratory and production.

How to develop a drug is basically out of his educational direction.

In China in 1984, no one understood this.

Domestic pharmaceutical companies may know how to pass domestic drug audits, but to pass the audits of drug regulatory agencies in major drug-consuming countries such as the United States, the United Kingdom, and France, Yang Rui must seek help from Zeneca.

This is not only for the safety of the drug itself, but also for the purpose of deferiprone to achieve cheap control of thalassemia.

The synthesis of an active substance of deferiprone is only the first step in the Long March. Next, Yang Rui will synthesize more active substances of deferiprone to find the most appropriate molecule of deferiprone. The same core molecule has different external bands. The side chains obtained may have completely different medicinal properties, and even more toxicity.

In order to complete the rest, the required cost may be millions of dollars, tens of millions of dollars, or even hundreds of millions of dollars.

No matter whether Yang Rui can afford such expenses, he has no reason to bear them.

The responsibility of pharmaceutical companies is to manufacture drugs, not charity, let alone alms. Deferiprone must be able to obtain sales exceeding costs in order to continue research and development and production lines, and Sinovel can continue to develop.

And to do this, there must be foreign patients to share the cost.

"Old Huang, you follow Arnold and Mr. Franky, and show him our results. Old Wei, let's continue." Yang Rui rubbed his hands and said directly in English: "The fifth synthesis experiment of deferiprone, start. "

...Mobile users please visit